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Some experimental and retrospective clinical studies signal an association between certain 
anaesthetic techniques and tumour metastasis following breast cancer surgery. Neutrophil 
Extracellular Trapping (NETosis) is an immunological process whereby neutrophils engulf tumour 
antigen then degranulate, leaving a serologic marker. NETosis expression among breast cancer 
patients is associated with an increased risk of metastasis. We investigated the effect of two 
distinct anaesthetic techniques on the expression of NETosis in women who underwent potentially 
curative breast cancer surgery.
Methods
In a parallel-group, randomised controlled trial, a subset of women (n=40), undergoing breast 
cancer resection surgery, who were partaking in a larger trial (NCT00418457), were randomly 
assigned to receive volatile general anaesthesia (GA) or propofol GA combined with paravertebral 
regional anaesthesia (PPA) for their surgery. Serum was taken and stored before and 24 hr post 
operatively. NETosis was measured by ELISA using Neutrophil Myeloperoxidase (MPO) and 
citrullinated histone H3 (H3Cit) biomarkers, which were the co-primary end-points. 
Results
Patient and breast cancer characteristics did not differ significantly between groups. Recurrence 
occurred in 7.5% patients. GA patients received more opioids and reported higher post-operative 
pain than PPA. There was no difference in postoperative MPO in GA vs PPA (10.5+6.6 vs 
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PPA (3.6+2.3 vs 4.0+5.9, p=0.80). NET expression did not differ before or after anaesthesia and 
surgery in either group, for either biomarker.
Conclusion
Anaesthetic technique did not affect NETosis expression in breast cancer patients, indicating that 
it is not a viable marker of the effect of anaesthetic technique on breast cancer recurrence.
Key Words
Anaesthesiology, general; Anaesthesiology, regional; Breast cancer;
Neutrophil extracellular trapping; Cancer, metastasis.
Editorial Comment
Neutrophil extracellular trapping (NETosis) is associated with increased risk of metastasis. This 
perioperative study in a small breast cancer surgery cohort did not reveal any difference in 
NETosis degree when exposed general anaesthesia with sevoflurane compared to 
propofol/paravertebral blockade.
Introduction
Breast cancer is both the most common cancer in women and the most common cause of cancer 
death amongst women globally.1,2 Mortality among women with a breast cancer diagnosis is 
usually from metastasis of the primary breast tumour3. 
At present, surgery of curative intent is the main treatment of breast cancer. It has been 
hypothesised that a number of factors relevant in the perioperative period, such as the surgical 
stress response, immune suppression, and direct effects of anaesthetic drugs might influence 
cancer progression to metastasis4. The surgical stress response releases pro-inflammatory 
cytokines and other molecules into the bloodstream that may affect the body’s post-operative 
immune response and create conditions that could facilitate residual tumour cell survival. This 
may later present as a clinical recurrence or metastasis.5
One of the immunological responses to cancer antigens is Neutrophil Extracellular Trapping 
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bloodstream, including proteins and chromatin which form an extracellular net ‘trapping’ the 
cancer cells. Release of cytotoxic enzymes within the NETosis net kills cancer cells and creates a 
physical barrier preventing the spread of disease6. Neutrophil myeloperoxidase (MPO) and 
citrullinated histone H3 (H3Cit) are specific proteins released during NETosis, which can be 
measured in serum. High serum NETosis levels are associated with cancer pathologies such as 
increased risk of recurrence, inflammation and thrombosis7,8,9.
It has been hypothesised that the anaesthetic technique during cancer surgery can influence cancer 
outcome by positively or negatively affecting the function of the immune system and other 
perioperative factors10. Earlier studies have shown that, in the serum of women who were given 
regional anaesthesia-analgesia using paravertebral block and propofol during cancer surgery, 
helpful immune responses were promoted, while in those who received volatile anaesthetic 
sevoflurane and opioid analgesia, these immune responses were inhibited11,12. 
Whether anaesthetic technique influences NETosis expression, a potential marker of metastatic 
risk, is unknown. Therefore, in this substudy within a larger clinical trial, we tested the hypothesis 
that women undergoing primary breast tumour resection with regional anaesthesia and propofol 
general anaesthesia have reduced postoperative serum expression of NETosis compared with 
women receiving volatile general anaesthesia and opioid analgesia.
Methods
After obtaining Institutional Review Board (IRB) approval and informed, written consent, both for 
participation in the larger, long term oncologic outcome trial (NCT-00418457) and this substudy), 
n=40 women due to undergo breast cancer resection of curative intent were enrolled in this study. 
The larger trial (NCT00418457) randomised women undergoing primary breast tumour resection 
to receive either regional anaesthesia and propofol general anaesthesia or sevoflurane volatile 
general anaesthesia and opioid analgesia.13. This subset of forty women consented in addition to 
donate a sample of peripheral blood for serum analysis just before induction of anaesthesia and 
again on Day 1 postoperatively. The patients were approached and enrolled the morning of 
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The inclusion criteria were: cancer Stage 1-3, nodal involvement stage 0-2, patients who were 
scheduled for a mastectomy or wide local excision with or without sentinel node biopsy and aged 
between 18-85 years old. Patients were excluded from the study if they had previous breast cancer 
surgery or inflammatory breast cancer, were scheduled for free flap reconstruction, had an 
American society of Anaesthesia (ASA) grade of 4 or higher, or had any contraindication to any 
aspect of anaesthetic technique.  
Patients were randomly assigned, in 1:1 allocation, to either of two cohorts which determined the 
type of anaesthetic used for their procedure. We used a table of random numbers to generate a 
sequence of digits 0 to 9. Even numbers were assigned to volatile GA, odd numbers to PPA, in 
blocks of 10 to ensure both study groups had similar numbers as the study progressed. Patients 
were assigned a study number. This was written on a single A4 page, together with the group 
assignment, and placed in a sequentially-numbered sealed envelope. The randomisation process 
was conducted just prior to induction of anaesthesia. The anaesthetists involved were obviously 
aware of the cohort allocations. Because the paravertebral anaesthesia was conducted awake, 
patients were also aware of their group allocation. However, investigators involved in the 
postoperative follow-up, which included blood sampling, follow up calls, data analysis and 
interpretation were masked to group allocation, therefore this was a single-blind trial. 
Patients randomised to receive volatile general anaesthesia and opioid analgesia were 
anaesthetised with fentanyl 1–2 µg.kg-1 and propofol 1.5 –2 mg.kg-1. Anaesthesia was maintained 
with sevoflurane (end-tidal concentrations 1–3%) in oxygen/air mixture. Intraoperatively, 
morphine 0.1–0.15 mg.kg-1 was given at the discretion of the anaesthetist. Patients received 
postoperative patient-controlled analgesia with morphine, bolus 1 mg, lockout 6 min, and 4 h dose 
limit 30 mg. Paracetamol 1 g i.v. was given to all patients during surgery.
Patients receiving propofol-paravertebral anaesthesia had a catheter inserted using a standard 
technique, into the ipsilateral paravertebral space at the level of the second thoracic vertebra. A 20 
ml bolus of levobupivacaine 0.25% was administered before surgery. Total i.v. general 
anaesthesia was then commenced using a target-controlled infusion of propofol. At induction, a 
dose of fentanyl 1–3 µg.kg-1 was administered. Laryngeal mask airway (LMA) was the default 
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continuous infusion of levobupivacaine 0.25% at 5–10 ml.h-1 via paravertebral catheter. 
Paravertebral catheters were removed at 24 h. Rescue analgesia if needed was triggered by a 
visual analogue scale (VAS) pain score ≥3, consisting of morphine 0.1 mg.kg-1 i.m. every 3–4 h as 
required.
Approximately 10 ml peripheral venous blood was taken from each participant at induction of 
general anaesthesia immediately preoperatively and on Day 1 (typically 20-24 hr postoperatively), 
into BD vaccutainerTM serum tubes (Becton, Dickinson and Company, Franklin Lakes, New 
Jersey, USA). The sample was centrifuged for 15 minutes at a rate of 4,000 rotations per minute. 
The remaining 2-3 ml plasma sample was then stored in a freezer at -80 C for later analysis. 
Samples were thawed and analysed for the enzyme-linked immunosorbent assay (ELISA) 
technique.  
The co-primary end-point of this trial was the two NETosis specific biomarkers, myeloperoxidase 
(MPO) and citrullinated histone H3 (CitH3). The measurements were made using commercially 
available ELISA kits for MPO and CitH3. MPO (Human MPO, R&D Systems, Inc. Minneapolis, 
MN 55413, USA, assay range: 1.56-10 ng.ml-1, sensitivity: 0.014 ng.ml-1), and CitH3 (CitH3 
Clone 11D3, CaymanChem, Ann Arbor, MI, USA, assay range: 1.56 – 10 ng.ml-1, sensitivity: 0.3 
ng.ml-1) in accordance with manufacturer’s instructions.
For the determination of MPO concentration, a sandwich ELISA technique was used with the anti-
MPO antibody pre-coated in the well of the plates. Each patient sample was divided into two 
duplicate samples which underwent the same testing procedures to enhance accuracy. The serum 
samples were diluted 1:50 with sample diluent. 50 µL  of diluted sample were added to each well, 
followed by 100 µL of assay diluent. The wells were covered by an adhesive strip and incubated 
for 2 h at room temperature on a horizontal orbital microplate shaker set to 500 rpm. 
Each well was aspirated and washed thoroughly 4 times using a wash buffer. The detection 
antibody used was an anti-MPO antibody conjugated with horseradish peroxidase (HRP). This 
conjugated antibody reacts strongly with hydrogen peroxide and TMB (3,3',5,5”-
tetramethylbenzidine). 200 µL of anti-Human MPO conjugated antibody were added to each well. 
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temperature on an orbital shaker at 500 rpm. The plate was aspirated and washed as before. 200 
µL of a 1:1 solution of hydrogen peroxide and TMB was added to each well and used as a 
substrate for HRP. The plate was incubated for 30 minutes at room temperature while protected 
from light. The HRP-TMB reduction reaction in each well was halted using a stop solution of 
sulphuric acid. This caused the colour of the solution to change from blue to yellow. The 
absorbance of light passed through the plate wells was immediately measured at 450 nm using a 
Molecular Devices microplate reader and SoftMax® Pro 5 software with wavelength correction 
set to 540 nm. For each plate, a standard curve was generated by measuring the optical densities at 
450nm of seven MPO standards of known concentration. This standard curve was used as a 
reference with which to calculate the MPO concentration in the diluted serum samples. The 
intensity of the signal produced per sample was proportional to the concentration of MPO 
(NETosis marker) present.
Similarly to MPO, the determination of CitH3 concentration was carried out using a sandwich 
ELISA technique. Assay buffer was used to dilute the serum sample, forming a 1:3 dilution. 100 
µL of standard and the diluted samples were placed in the wells (pre-coated with anti-CitH3 
antibody), with the samples being placed as duplicates. The wells were covered and incubated for 
two hours at room temperature on an orbital shaker. Following this incubation period, the wells 
were washed 4 times with a wash buffer and then 100 µL of HRP Conjugate working solution was 
added to each plate. This was incubated for one hour. Again, following this incubation period, the 
plates were thoroughly washed 4 times with wash buffer. 100 µL of TMB Substrate Solution was 
added to each well of the plate and the plate was then covered and left to incubate at room 
temperature for 30 minutes in the dark on an orbital shaker. Immediately after this final incubation 
period, 100 µL of HRP Stop Solution was added to each well of the plate and a colour change of 
blue to yellow was seen (while colourless wells remained colourless). Finally, using a microplate 
reader, the plate was read at a wavelength of 450 nm. A standard curve was generated for each 
plate using seven CitH3 standards of known concentration. This was used as a reference for 
calculation of CitH3 concentrations in each serum sample. The coefficient of variation was 
obtained for both MPO and CitH3 concentrations. 
Patient characteristics were recorded including: age, Body-Mass Index (BMI), ethnicity, their 
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previous chemotherapy or radiation therapy. Characteristics about the tumour were also recorded 
including: which hormone receptors were present, the TNM stage, the histology grade of the 
tumour and a Nottingham Hill Prognostic Index was then calculated. Surgical characteristics were 
recorded during surgery and immediately post-operatively including: the type of procedure, the 
dose of intraoperative opioids given, the highest heart rate (HR) and lowest mean arterial pressure 
(MAP) intraoperatively, the total blood lost during the surgery and the post-operative pain score 
on VRS and the subsequent dose of opioids if required.
Statistical Analysis
The data collected was placed onto an excel spreadsheet and then copied and transferred onto 
Graph Pad Prism v8TM for statistical analysis. Data was inspected for normal distribution, using 
the Kolmogorov-Smirnov test. If normal distribution was confirmed, differences between 
independent groups were compared using an unpaired t test, while pre and post-operative NETosis 
levels within groups were compared using a paired t test. P< 0.05 was deemed statistically 
significant. 
Previous serum estimations of NETosis MPO values indicated typical values in the order of 10-12 
ng.ml-1 with standard deviation in the order of 3 ng ml-1. Taking a 20% reduction of 2.0 ng ml-1 as 
being scientifically significant, and assuming a Type I error of 0.05 and Type 2 error of 0.2, then 
n=18 patients would be required each group to have 80% power to detect this difference. We 
enrolled n=20 patients each group to allow for missing data. 
Results
The serum samples of 40 women were analysed. 
The study flow sheet, according to CONSORT guidelines, is shown in Figure 1.
The physical characteristics of the patients were similar between the two cohorts as seen in Table 
1. There were no significant differences in surgical or anaesthesiology characteristics between the 
two groups, except for intraoperative opioid, one-hour post-operative pain and first morning 
opioid use, all of which were greater in the GA group, as expected. The Tumour Node Metastasis 
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Prognostic Index and other cancer characteristics also showed no significant difference between 
the two anaesthetic groups (Table 2). 
Table 3 displays the biomarkers of MPO and H3Cit, which represent the expression of NETosis. 
Regarding MPO, there was no difference preoperatively between the GA and PPA cohorts (8.6 + 
4.7 vs 10.4 + 6.3 respectively, p= 0.28). The groups were similar again post operatively (10.5 + 
6.6 vs 11.5 + 4.7 respectively, p = 0.60). There was no difference within the PPA cohort post 
operatively (11.5 + 4.7 vs 10.4 + 6.3, p= 0.44). There was also no difference within the GA cohort 
post operatively (10.5 + 6.6 vs 8.6 + 4.7, p=0.22). The coefficient of variation between the 2 
duplicates for the MPO testing, ranged from 0-12 for the GA cohort compared to 0-14 for the 
PPA. 
Regarding H3Cit, there was no difference preoperatively between GA and PPA cohorts (3.4 + 1.7 
vs 3.1 + 2.1 respectively, p=0.62). The groups were similar again postoperatively (3.6 + 2.3 vs 4.0 
+ 5.9 respectively, p= 0.8). There was no difference within the PPA cohort post operatively (4.0 + 
5.9 vs 3.1 + 2.1, p=0.43). There was also no difference post operatively in the GA cohort (3.4 + 
1.7 vs 3.6 + 2.3, p= 0.70). The coefficient of variation for the H3Cit ranged from 0-15% for the 
GA cohort compared to 0-19% for the PPA. 
Our study of n=40 women showed a breast cancer recurrence rate of 7.5% (n= 3 cases). The 
median post-operative value for MPO concentration in the n=3 patients with recurrence was 11 ng 
mL-1, comparable to the mean values of the two groups shown in Table 3. The median post-
operative value for CitH3 concentration in the n=3 patients with recurrence was 3.5 ng mL-1, 
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Discussion
This pilot, prospective, randomised, single-blind, single-centre trial evaluated the effects of two 
different anaesthetic techniques on serum expression of NETosis markers (MPO and H3Cit). The 
results showed that there was no difference in NETosis expression post-operatively with the use of 
volatile general anaesthesia or propofol general anaesthesia combined with paravertebral regional 
anaesthesia.
During NETosis, DNA histones undergo citrullination which causes chromatin decondensation 
8,9,15-17. There are certain factors required for NET release, regardless of the stimulus that has 
initiated NET formation. These include myeloperoxidase (MPO) and neutrophil elastase (NE), 
which are found attached to the neutrophil extracellular traps that have been released during 
NETosis15-17. Therefore, high levels of CitH3 and MPO indicate high levels of NETosis which is 
associated with increased metastatic risk.14-16 NETosis is involved in the inflammatory response 
and it has been observed that NETs also have a direct cytotoxic effect on the endothelium.17 In 
breast cancer patients, NETosis has been associated with an increase in disease progression, 
metastasis and venous thromboembolism.15 The exact mechanism by which it causes metastasis is 
still being determined.8,9, 14-18 Understanding the role of neutrophils, and NETosis, in cancer is 
important due to the implications they have on cancer patients and the role they play in cancer 
progression.
Previous research shows that tumor-induced neutrophils are more prone to forming NETs than 
other neutrophils 16 This was observed using murine models of chronic myelogenous leukaemia, 
breast and lung cancer. Whether breast tumour is more likely to induce neutrophils is unknown. 
Previous studies also investigated whether NETosis could be a possible risk factor for cancer 
pathologies such as thrombosis and metastases 17, 18.   When human lung cancer cells were 
incubated with neutrophils and PMA to induce NET formation, there was a resultant increase in 
migration and invasion of the cells in the presence of intact NETs. This suggests that NETosis 
plays a role in metastasis of cancer cells17, 19. Another study, using caecal ligation and puncture 
(CLP) assay of sepsis in mice, showed that NETs can sequester tumour cells and can survive and 
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Experimental and clinical retrospective studies have investigated the association between the type 
of anaesthetic used during cancer resection surgery and recurrence11-14,19-21. Propofol, a commonly 
used anaesthetic agent, has been shown to possess anti-inflammatory properties as well as 
stimulatory effects on immune function, which could have beneficial effects for cancer recurrence 
19. Volatile anaesthetics and opioids can impair immune function and reduce apoptotic effect in 
certain cell lines, such as in human colon cancer cells. A sevoflurane and opioid technique was 
shown to reduce apoptosis in breast cancer cells when compared to the use of a propofol and 
paravertebral anaesthetic technique.11 Other studies have evaluated the effects of different 
anaesthetic drugs on the post-operative immune response either in a favourable or detrimental way 
in relation to cancer reoccurrence or metastases 12-14,20-21. A recent, similarly-designed study 
showed that anaesthetic technique may have an effect on NETosis. This group observed that when 
lidocaine was added to either volatile sevoflurane or propofol-total intravenous anaesthesia 
(TIVA), there was a reduction in NETosis expression 14 among women undergoing surgery for 
breast cancer.
The large clinical trial evaluating the effect of anaesthetic technique on breast cancer outcomes, 
which these patients participated in, had an overall recurrence rate of 10%, with no difference in 
oncologic outcomes between the anaesthetic techniques evaluated.13 Our present study found 
similarities between the post-operative MPO and CitH3 concentrations for those with and without 
recurrence which suggests that NETosis may not be a discriminating factor for predicting 
metastatic disease. The results of this study suggest that NETosis expression is not affected by 
anaesthetic technique. However, our small population size could have played a role in these 
findings. Our study was designed to have 80% to detect a meaningful difference in NETosis 
expression, therefore it is possible that a Type II error occurred. Nonetheless, we believe this is a 
reasonable sample size for this pilot study to evaluate this novel hypothesis. Also, the use of 
ELISA for measuring MPO in serum was shown to be accurate and precise by intra‐ and 
inter‐assay coefficients of variation of <10% for MPO concentrations ranging from 0.5 to 50 
ng/ml and by the similarity between the standard curve and curves obtained with successive 
dilutions of MPO‐rich serum samples 14-17,22
Since the women were all breast cancer patients who were undergoing cancer resection surgery 
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of NETosis would be solely due to the type of anaesthetic technique that was used. However, as in 
the results, neither of the anaesthetic techniques used was shown to have any significant effects on 
the NETosis expression post operatively. The only difference seen post operatively between the 
cohorts was in the use of intra operative opioids and the post-operative pain reported on the visual 
analog scale. As expected, those who received GA combined with paravertebral regional 
anaesthesia reported less post-operative pain and required little to no intra operative opioids.  
Opioids themselves have been associated with an increase in tumour metastases, but the data is 
conflicting and further research and clinical trials are required 23.
A limitation of this study is the small sample size. A strength is its randomised double-blind 
design, thus reducing bias. The fact that two established sensitive tests for NETosis were used 
increases the overall sensitivity of the study as a true level of NETosis expression. 
In conclusion, this pilot, prospective, randomised, double-blind, single-centre trial has shown that 
anaesthetic technique has no effect on the expression of NETosis as a marker of metastatic disease 
in breast cancer. This implies that NETosis is not influenced by these anaesthetic techniques and 
that it may not be a reliable marker in future trials evaluating the effect of these anaesthetic 
techniques on cancer recurrence. 
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Table 1: Patient and Surgical Characteristics. 






Age (yr) 57 (10) 59 (9)  
BMI 29 (6) 29 (7)  
Caucasian Race  20 (100%)  20 (100%)  
ASA physical status    
1 11 (55%) 10 (59%)  
2 8 (40%) 5 (29%)  
3 1 (5%) 2 (12%)  
Duration of 
Anaesthesia (mins) 
73 (16) 85 (45) 0.25 
Wide Local Excision 
surgery  
16 (80%) 18 (90%) 0.28 
Full Mastectomy  
 
4 (20%) 2 (10%) 0.28 
Intraoperative 
Opioids (mg) 
10 (10-10) 0 (0-0) 0.0001 
Intraoperative 
Lowest MAP 
59 (8) 65 (16) 0.09 
Intraoperative 
Highest HR 
78 (13) 78 (8) 0.99 
Intraoperative Blood 
Loss (ml) 
314 (166) 290 (129) 0.61 
First Morning total 
Opioids (mg) 
5 (0-10) 0 (0-0) 0.003 
Postoperative Pain 4 (3-4) 0 (0-1) <0.0001 
Previous 
Chemotherapy 
0   1 (5%) 0.30 
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Table 2: Cancer Characteristics.  




17 (85%) 19 (100%) 0.59 
Progesterone 
Receptor positive  
15 (79%) 13 (76%) 0.86 
HER2 Receptor 
positive 
5 (26%) 4 (22%) 0.78 
Closest Tumour 
Margins 
3.8 (2.9) 4.2 (3) 0.66 
TNM Stage   0.25 
0 1 (5%) 0  
1 6 (30%) 11 (55%)  
2A 8 (40%) 6 (30%)  
2B  3 (15%) 1 (5%)  
3A 1 (5%) 2 (10%)  
4 1 (5%) 0  
Histology Grade   0.09 
1 1 (5%) 6 (30%)  
2 12 (60%) 8 (40%)  
3 7 (35%) 6 (30%)  
Nottingham 
Prognostic Index 
4.3 (1) 3.8 (1.4) 0.22 
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Table 3: NETosis serology values. All data shown is mean (standard deviation) 
 
 
Parameter GA PPA P value 
Pre op MPO (ng ml
-1
) 8.6 (4.7) 10.4 (6.3) 0.28  
Post op MPO (ng ml
-1
) 10.5 (6.6) 11.5 (4.7) 0.60 
Pre op H3Cit (ng ml
-1
) 3.4 (1.7) 3.1 (2.1) 0.62 
Post op H3Cit (ng ml
-1
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Figure 1:  Trial profile
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